Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized, Single-blind Safety and Tolerability Clinical Trial of Different Doses of the Immunotherapeutic Drug Mobilan (M-VM3) and Placebo in Patients With Prostate Cancer

NCT02654938 is registered in ClinicalTrials.gov with Panacela Labs LLC as lead sponsor.

NCT NCT02654938
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02654938 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized, Single-blind Safety and Tolerability Clinical Trial of Different Doses of the Immunotherapeutic Drug Mobilan (M-VM3) and Placebo in Patients With Prostate Cancer
Lead sponsor
Panacela Labs LLC
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2015
Completion date
September 30, 2017
Enrollment
32 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer